ANI Pharmaceuticals, Inc.
ANIP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $1 | $1 |
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 26.2% | 53.9% | 46.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 59.3% | 62.7% | 56.1% | 53.5% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 10.3% | 21.9% | 7.9% | 1.4% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -3% | 3.9% | -15.1% | -19.7% |
| EPS Diluted | -1.04 | 0.94 | -3.05 | -3.4 |
| % Growth | -210.6% | 130.8% | 10.3% | – |
| Operating Cash Flow | $0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$0 |